Forecast

There is no analyst data available for this company.

News Go to news feed

NanoRepro gives revenue guidance: to rise from around €18m in 2026 to €40m in 2030

The board of NanoRepro expects consolidated group revenue of around €18m for 2026, which would be about 12.5% growth versus 2025 (around €16m). Revenue is forecast to increase organically to about €28m by 2028, and management is targeting roughly €40m by 2030 through organic growth and targeted acquisitions. The plan is based on scaling existing brands, consolidating central functions, and expanding margin-strong business areas. » More on de.investing.com
NanoRepro: supervisory board member Stiller buys 2,688 shares at €1.86

Dr. Olaf Stiller, a member of NanoRepro’s supervisory board, reported on 18 August 2026 that he purchased 2,688 shares on 17 August 2026 at €1.86 each. Previously, on 31 July 2026 Stiller had bought 5,262 shares at €1.90 each. The stock showed little movement in trading; market capitalization €26.28 million, free float 13,903,603 shares. » More on finanzen.net
NanoRepro board member Jüngst acquires 5,435 shares

On 29 May 2026 Lisa Jüngst bought 5,435 NanoRepro shares at €1.84 each; the transaction was reported on 1 June 2026. The stock showed only slight price movement in FSE trading and closed around €1.73–1.74. Previously, additional purchases by Jüngst of 6,984 shares at €1.84 each had already been recorded. » More on finanzen.net

Historical dividends Dividends

All dividend metrics All metrics

In 2023, NanoRepro has already paid €0.15 in dividends. The last payout was in June 2023.

Financials

In the last quarter, NanoRepro had revenue of €1.91m and net profit of -€1.14m

(EUR)	December 2025	YoY
Revenue	1.91m	-
Gross profit	224.2k	-
Net profit	-1.14m	-
EBITDA	-1.28m	-

Fundamentals

Metric	Value
Market capitalization	€22.45m
Number of shares	12.61m
52-week high/low	€2.40 - €1.31
Dividends	No
Beta	0.52
P/E ratio	-11.30
PEG ratio	3.16
P/B ratio	0.62
P/S ratio	5.18

Company profile

Die NanoRepro AG entwickelt, produziert und vertreibt in Deutschland und international diagnostische Schnelltests und Nahrungsergänzungsmittel für den privaten und professionellen Gebrauch. Das Unternehmen bietet Produkte in den Bereichen Familienplanung und Krankheitserkennung sowie Nahrungsmittelunverträglichkeiten, Allergien und Infektionskrankheiten an. Das Unternehmen bietet diagnostische Schnelltests an, darunter Produkte für die Bereiche Allergie, Familienplanung und Gesundheitsvorsorge; Point-of-Care-Tests für Krankenhäuser und Arztpraxen zum Nachweis von HIV, humanem kardialem Troponin I, D-Dimer, Streptokokken-Antigen, Influenza-Typ-A- und -B-Antigenen und Mikroalbumin; immunchromatographische Lateral-Flow-Tests für den diagnostischen Nachweis von Biomarkern sowie einen SARS-CoV-2-Antikörper-Schnelltest und einen Corona-Antigen-Schnelltest. Es bietet auch Nahrungsergänzungsmittel für Männer und Frauen über Online-Shops sowie über Apotheken an. Der Hauptsitz des Unternehmens befindet sich in Marburg, Deutschland.